Press Releases
Contact: Robert Albright |
Phone: 919-549-7500 ext.123 |
Five More Companies Selected for CED's Venture 2003
Final Application Deadline Slated for Jan. 23; GlaxoSmithKline's Ingram to Deliver Keynote Address
January 20, 2003, Research Triangle Park, NC - The Council for Entrepreneurial Development (CED) has chosen five additional companies to present at Venture 2003. Other interested companies are encouraged to apply by Jan. 23 for consideration in the final selection round. The conference, scheduled for April 22-23, 2003, in Chapel Hill, NC, will continue its 20-year tradition of showcasing North Carolina's hottest investment opportunities to venture capitalists and financiers from throughout the United States.
Bob Ingram, Vice Chairman of Pharmaceuticals for GlaxoSmithKline, has also agreed to deliver a keynote address at the conference. In late December 2002, Ingram retired from his position as Chief Operating Officer and President of Pharmaceutical Operations for GSK.
"Bob Ingram's reputation for leadership and management excellence is without peer," said Steve Nelson, a partner with the Wakefield Group and co-chair of Venture 2003. "We are delighted he is going to share his wisdom with us."
In addition, Nelson said the newly selected presenting companies "would be an early showcase into the area's winning companies of the future."
The five companies recently selected to present at Venture 2003 include:
- Bloodhound Inc. (Durham, NC - www.bloodhoundinc.com)
- Founded in 1997, Bloodhound Inc. is an application service provider
(ASP) specializing in medical claims overpayment protection services
and medical billing data analysis. Bloodhound's flagship product safeguards
insurers and other at-risk medical payment organizations from medical
claims overpayment.
- Regado Biosciences (Durham, NC) - Regado Biosciences
is an RTP-based company developing the first generation of regulatable
therapeutics. Its proprietary technology allows Regado to generate
highly specific antidotes for each new drug it develops. The rational
design of drug-antidote pairs represents a new paradigm for developing
safer therapeutics that addresses multi-billion dollar markets in
acute care medicine.
- Syntherica Corp. (Durham, NC) - The proprietary
SynthetideTM technology of
Syntherica Corp. (formerly Sylvanus Pharma, Inc.) creates synthetic
antibodies that mimic the important features of antibodies, such as
specificity and affinity, but can be developed in one-tenth the time
of natural antibodies. The company's technology provides a new approach
to such intractable diseases as HIV/AIDS, where natural antibodies
have proven ineffective.
- TransTech Pharma, Inc. (High Point, NC - www.ttpharma.com)
- TransTech Pharma is a drug discovery company that has developed
and implemented a proprietary and efficient "drug discovery engine"
called TTP Translational TechnologyTM.
This technology platform utilizes and translates genomic and proteomic
data into safe and effective small molecule therapeutics in high throughput
fashion, bypassing most of the classical requirements and bottlenecks
in drug discovery.
- ViASIC (Durham, NC - www.viasic.com) - ViASIC provides leading Electronic Design Automation (EDA) solutions that connect physical synthesis to manufacturing for integrated circuit (IC) designers. ViASIC also offers patent-pending technology, available for license to ASIC manufacturers and suppliers, designers and end-users.
During the first selection round in December 2002, CED chose six other companies to participate in the conference:
- Biolex, Inc. (Pittsboro, NC - www.biolex.com)
- Kucera Pharmaceutical Co. (Winston-Salem, NC
- www.kucerapharma.com)
- MindValve Inc. (Charlotte, NC - www.mindvalve.com)
- Oriel Therapeutics, Inc. (Research Triangle Park,
NC - www.orieltherapeutics.com)
- Stemco Biomedical (Durham, NC - www.stemcobiomedical.com)
- Total Billings (Fayetteville, NC - www.totalbillings.com)
Since 1999, Venture presenters have raised over $1.5 billion in venture capital. The Venture 2003 Selection Committee, which includes professional venture capitalists and angel investors from throughout the Southeast, is seeking high growth companies from an array of industries that are looking to raise either initial or subsequent rounds of professional equity capital.
In addition to company presentations, Venture 2003 will include leading industry speakers, extensive networking opportunities and exclusive investor-only events. For more information on applying to present or general registration, visit www.cednc.org/venture/2003.
About Venture 2003: CED's upcoming 20th annual Venture 2003 - where great minds meet smart money - is scheduled for April 22-23, 2003 at The Friday Center in Chapel Hill, NC. Last year's conference, Venture 2002 drew a crowd of more than 850 investors, service professionals, entrepreneurs and others involved in the entrepreneurial funding process from throughout the United States. Interested parties should visit the conference Web site at www.cednc.org/venture/2003.
About CED: The Council for Entrepreneurial Development, located in Research Triangle Park, NC, is a private, non-profit organization formed in 1984 to stimulate the creation and growth of high-impact companies in the greater Research Triangle region. CED provides education, mentoring and capital formation resources to new and existing high-growth entrepreneurs through annual conferences, seminars, workshops and monthly programs on entrepreneurial management and finance. CED is the largest entrepreneurial support organization in the nation with more than 5,000 members representing 1,200 entrepreneurial companies, financiers and professional firms. www.cednc.org